↓ SCROLL TO SEE MORE ↑

What are you looking for?

News

Kyrgyzstan to host Phase 3 trials of Turkish-made COVID-19 vaccine

Kyrgyzstan to host Phase 3 trials of Turkish-made COVID-19 vaccine

Phase 3 trials of the Turkish-developed COVID-19 vaccine Turkovac will take place in Kyrgyzstan, Vice President Fuat Oktay said.

Oktay announced the trials in Kyrgyzstan following his trip to the Central Asian republic.

“We are making an unremitting effort to offer our domestic vaccine to the service of not only our nation, but all humanity,” the vice president said.

Oktay also said that the Turkish government was in talks with several other countries over Turkovac studies.

“Negotiations continue with many countries, including Pakistan, Azerbaijan, Argentina, Colombia and Poland, on holding Phase 3 trials,” he said.

Oktay noted that important steps have been taken for Turkovac to become a vaccine used all over the world and gain international recognition.

Turkovac’s Phase 3 trials kicked off in Turkey in late June, and this week Health Minister Fahrettin Koca said the Turkish vaccine was nearly ready to apply for emergency use approval.

News

More than 60 million people are already using the Turkish e-Government (e-Devlet) public services system, said Ali Taha Koch, the head of the Office...

News

Turkish grocer takes baby crow under his wing. Naming his new companion Sakir, 52-year-old Tekin Talsik shared his home and shop in the province...

News

Even though the number of fatalities is somewhat increasing, the coronavirus pandemic is no longer a top concern for the Turkish public as specialists...

News

376,924 foreign tourists visited Turkey on cruise ships in the first seven months of this year, with the Aegean Tourism Center of Kusadasi hosting...

News

Türkiye’s President Recep Tayyip Erdogan on Tuesday inaugurated the 5th Islamic Solidarity Games in the country’s central Konya province. “I am starting the sports...

News

The new version of the BioNTech/Pfizer coronavirus vaccine, modified for the most recent omicron subvariant, is currently the subject of a rolling review, according...